English

The exercise period for warrants of series TO 4 commences today

Report this content

Today is the first day for the exercise of Phase Holographic Imaging PHI AB's ("PHI" or "Company") warrants of series TO 4 ("TO 4") which were issued in connection with the preferential issue of units that the Company carried out during 2022. The period lasts until October 3, 2024. Holders of TO 4 have the right to subscribe for one (1) new share in PHI for each TO 4 at a price of SEK 4.63 per share. Through full use of TO 4, the Company can receive a maximum of approximately SEK 6.2 million before issue costs. An information document is available on the respective websites of PHI (www.phiab.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se).

In the Spring of 2022, PHI carried out a rights issue which brought the Company approximately SEK 57.6 million before issue costs. Through the rights issue, 1,346,162 warrants of series TO 4 were issued. Each TO 4 entitles the holder to subscribe for one (1) new share in PHI during the exercise period, which runs September 12-October 3, 2024. The exercise price for TO 4 has been set at SEK 4.63 per share. In the event of full utilization of warrants of series TO 4, approximately SEK 6.2 million will be added to the Company before issue costs.

Complete terms and conditions for warrants of series TO 4 are available on the Company's website (www.phiab.com). An information sheet containing summary information about the warrant exercise is also available on PHI’s, Sedermera Corporate Finance AB's (www.sedermera.se) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites.

TO 4 in short

  • Exercise price: Each TO 4 entitles the warrant holder to subscribe for one (1) new share in PHI at a price of SEK 4.63 per share.
  • Issue volume: There are 1,346,162 issued TO 4. At full utilization of TO 4, PHI receives approx. SEK 6.2 million before issue costs.
  • Number of outstanding shares prior to warrant exercise: 26,192,925 shares.
  • Short name and ISIN: TO 4 are traded at Spotlight Stock Market under short name “PHI TO 4” and with ISIN SE0017766462.

Important dates

  • 12 September 2024: Exercise period commences
  • 1 October 2024: Last day of trading in TO 4
  • 3 October 2024: Exercise period ends
  • 4 October 2024: Planned date for publication of outcome of the exercise
  • 18 October 2024: Planned date for change from interim shares to shares

Shares and share capital

Upon full utilization of TO 4, the number of shares in PHI will increase by 1,346,162 shares to a total of 27,539,087 shares and the share capital will increase by SEK 269,232.40 to SEK 5,507,817.40. The dilution at full utilization amounts to approximately 4.9 percent of the capital and votes.

Advisors

In connection with the warrant exercise, PHI has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent

For information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
Web: www.sedermera.se

For additional information, please contact:
Lisa Bodily
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis

About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.  

Subscribe

Documents & Links